Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| LifeMD, Inc.LFMD · Entity 6521 | Director · Consultant | June 20, 2023 | June 22, 2023 |
| MYOMO, INC.MYO · Entity 7135 | Director | June 25, 2026 | June 26, 2026 |
| Modular Medical, Inc.MODD · Entity 7488 | Director | June 30, 2023 | July 05, 2023 |
| OptimizeRx CorpOPRX · Entity 213 | Director · CEO | February 14, 2025 | February 20, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
LifeMD, Inc.
Report date June 20, 2023 · Filed June 22, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 450,000 |
Reported balance
After 2023-06-20 transaction · row 1
1 source rowRow 1 · 2023-06-20 · Grant · Acquired 75,000 · Balance 450,000 F1: The grant of restricted stock shares vests 37,500 shares immediately and the remaining 37,500 shares on the second anniversary of the date of grant. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.37 · Expires 2028-06-20 | Direct | 37,500 |
Reported balance
After 2023-06-20 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-06-20 · Grant · Acquired 37,500 · Balance 37,500 F2: The options vest on the second anniversary of the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: The grant of restricted stock shares vests 37,500 shares immediately and the remaining 37,500 shares on the second anniversary of the date of grant.
F2: The options vest on the second anniversary of the date of grant.
MYOMO, INC.
Report date June 25, 2026 · Filed June 26, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 123,704 |
Reported balance
After 2026-06-25 transaction · row 1
1 source rowRow 1 · 2026-06-25 · Grant · Acquired 78,704 · Balance 123,704 F1: Represents grant of Restricted Stock Units under the Issuer's 2018 Stock Option and Incentive Plan, each representing a contingent right to receive one share of the Issuer's common stock. Such Restricted Stock Units vest in four equal quarterly installments beginning on September 9, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents grant of Restricted Stock Units under the Issuer's 2018 Stock Option and Incentive Plan, each representing a contingent right to receive one share of the Issuer's common stock. Such Restricted Stock Units vest in four equal quarterly installments beginning on September 9, 2026.
Modular Medical, Inc.
Report date June 30, 2023 · Filed July 05, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 91,605 |
Reported balance
After 2023-06-30 transaction · row 1
1 source rowRow 1 · 2023-06-30 · Grant · Acquired 2,500 · Balance 91,605 F1: The Issuer issued these shares to the Reporting Person in accordance with its Outside Director Compensation Plan. |
Filing footnotes · ownership attribution and instrument terms
F1: The Issuer issued these shares to the Reporting Person in accordance with its Outside Director Compensation Plan.
OptimizeRx Corp
Report date February 14, 2025 · Filed February 20, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 600,852 |
Reported balance
After 2025-02-14 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2025-02-14 · Tax withholding · Disposed 401 · Balance 600,852 F1: These shares were withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations. Such withholding is treated as a disposition of securities under Section 16 of the Securities Exchange Act of 1934, as amended. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares were withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations. Such withholding is treated as a disposition of securities under Section 16 of the Securities Exchange Act of 1934, as amended.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Augmedix, Inc.
Report date October 02, 2024 · Filed October 04, 2024
Section 16 reporting ended · disclosed 2024-10-04. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2024-10-02 transaction · row 1
1 source rowRow 1 · 2024-10-02 · Disposition to issuer · Disposed 162,583 · Balance 0 F1: Disposed of in connection with the merger of Augmedix, Inc. ("Augmedix") with and into Anderson Merger Sub, Inc. (the "Merger Sub"), effective October 2, 2024 (the "Merger"), pursuant to the Agreement and Plan of Merger dated as of July 19, 2024, among Augmedix, Commure, Inc., and Merger Sub (the "Merger Agreement"). In connection with the Merger, the shares listed were canceled and converted into the right to receive $2.35 per share, without interest (the "Merger Consideration"), and subject to applicable tax withholdings. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.80 · Expires 2032-03-27 | Direct | 0 |
Reported balance
After 2024-10-02 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-10-02 · Disposition to issuer · Disposed 50,000 · Balance 0 F2: Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each stock option (the "Company Option") that was outstanding, unexercised and vested as of immediately prior to the Effective Time with a per share exercise price ("Per Share Exercise Price") that was less than the Merger Consideration, was cancelled and converted into the right to receive an amount in cash (without interest and less any applicable withholding taxes) equal to the product of (i) the aggregate number of shares of common stock of Augmedix (the "Company Common Stock") underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the Per Share Exercise Price of such Company Option. Each Company Option that had a Per Share Exercise Price that was equal to or exceeded the amount of the Merger Consideration at the Effective Time was cancelled for no consideration. F3: Each Company Option that was unvested and had a Per Share Exercise Price that was less than the amount of the Merger Consideration at the Effective Time was replaced with a cash incentive program, which in either case preserves the compensation elements and vesting terms of the Company Option. F4: The option is granted under the Augmedix 2020 Equity Incentive Plan. The option will vest monthly in equal increments for one (1) year starting on March 28, 2022, subject to the Reporting Person's provision of service to the Issuer on each vesting date, and will be fully vested on March 28, 2023. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed of in connection with the merger of Augmedix, Inc. ("Augmedix") with and into Anderson Merger Sub, Inc. (the "Merger Sub"), effective October 2, 2024 (the "Merger"), pursuant to the Agreement and Plan of Merger dated as of July 19, 2024, among Augmedix, Commure, Inc., and Merger Sub (the "Merger Agreement"). In connection with the Merger, the shares listed were canceled and converted into the right to receive $2.35 per share, without interest (the "Merger Consideration"), and subject to applicable tax withholdings.
F2: Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each stock option (the "Company Option") that was outstanding, unexercised and vested as of immediately prior to the Effective Time with a per share exercise price ("Per Share Exercise Price") that was less than the Merger Consideration, was cancelled and converted into the right to receive an amount in cash (without interest and less any applicable withholding taxes) equal to the product of (i) the aggregate number of shares of common stock of Augmedix (the "Company Common Stock") underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the Per Share Exercise Price of such Company Option. Each Company Option that had a Per Share Exercise Price that was equal to or exceeded the amount of the Merger Consideration at the Effective Time was cancelled for no consideration.
F3: Each Company Option that was unvested and had a Per Share Exercise Price that was less than the amount of the Merger Consideration at the Effective Time was replaced with a cash incentive program, which in either case preserves the compensation elements and vesting terms of the Company Option.
F4: The option is granted under the Augmedix 2020 Equity Incentive Plan. The option will vest monthly in equal increments for one (1) year starting on March 28, 2022, subject to the Reporting Person's provision of service to the Issuer on each vesting date, and will be fully vested on March 28, 2023.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 15, 2021 Filed Dec 17, 2021 21:45 UTC | OptimizeRx Corp OPRX · Entity 213 | SaleCommon Stock (pursuant to 10B5-1 plan) | 16,666 | $54.55 | $909,130.30 |
DisclosureSEC source: 0001213900-21-066031 · ownership.xml · nonDerivative · entry 1 FEBBO WILLIAM J · CIK 0001413987 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 469,377 F1 · security: These shares sold pursuant to a plan of disposition adopted on May 28, 2021 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| November 15, 2021 Filed Nov 17, 2021 21:45 UTC | OptimizeRx Corp OPRX · Entity 213 | SaleCommon Stock (pursuant to 10B5-1 plan) | 16,666 | $82.18 | $1,369,611.88 |
DisclosureSEC source: 0001213900-21-060341 · ownership.xml · nonDerivative · entry 1 FEBBO WILLIAM J · CIK 0001413987 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 486,043 F1 · security: These shares sold pursuant to a plan of disposition adopted on May 28, 2021 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| October 15, 2021 Filed Oct 19, 2021 20:45 UTC | OptimizeRx Corp OPRX · Entity 213 | GrantPerformance Stock Units · Derivative | 182,398 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-21-053524 · ownership.xml · derivative · entry 2 FEBBO WILLIAM J · CIK 0001413987 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 182,398 Underlying: Common Stock · 182,398 shares Expires 2026-10-15 F2 · derivative.exercise_price: Each performance stock unit represents a contingent right to receive one share of the OptimizeRx's common stock. The first 33% of the performance stock units are earned upon OptimizeRx common stock achieving an average closing price per share of $98.87 or higher for 30 consecutive trading days during the five-year performance period. Another 33% of the performance stock units are earned upon OptimizeRx common stock achieving an average closing price per share of $131.82 or higher for 30 consecutive trading days during the five-year performance period. A final 34% of the performance stock units are earned upon OptimizeRx common stock achieving an average closing price per share of $164.78 or higher for 30 consecutive trading days during the five-year performance period. If earned, the performance stock units will, subject to certain exceptions, vest ratably on the first anniversary of such performance achievement. Any performance stock unit that has not been earned and vested as of the fifth anniversary of the grant date will be forfeited. Vesting of the performance stock units shall accelerate upon a qualifying termination. F2 · derivative.exercise_date: Each performance stock unit represents a contingent right to receive one share of the OptimizeRx's common stock. The first 33% of the performance stock units are earned upon OptimizeRx common stock achieving an average closing price per share of $98.87 or higher for 30 consecutive trading days during the five-year performance period. Another 33% of the performance stock units are earned upon OptimizeRx common stock achieving an average closing price per share of $131.82 or higher for 30 consecutive trading days during the five-year performance period. A final 34% of the performance stock units are earned upon OptimizeRx common stock achieving an average closing price per share of $164.78 or higher for 30 consecutive trading days during the five-year performance period. If earned, the performance stock units will, subject to certain exceptions, vest ratably on the first anniversary of such performance achievement. Any performance stock unit that has not been earned and vested as of the fifth anniversary of the grant date will be forfeited. Vesting of the performance stock units shall accelerate upon a qualifying termination. Read SEC document |
| October 15, 2021 Filed Oct 19, 2021 20:45 UTC | OptimizeRx Corp OPRX · Entity 213 | SaleCommon Stock (pursuant to 10B5-1 plan) | 16,666 | $84.20 | $1,403,277.20 |
DisclosureSEC source: 0001213900-21-053524 · ownership.xml · nonDerivative · entry 1 FEBBO WILLIAM J · CIK 0001413987 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 502,709 F1 · security: These shares sold pursuant to a plan of disposition adopted on May 28, 2021 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| September 30, 2021 Filed Oct 4, 2021 17:28 UTC | Modular Medical, Inc. MODD · Entity 7488 | GrantCommon Stock | 8,389 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001019056-21-000519 · febbo.xml · nonDerivative · entry 1 FEBBO WILLIAM J · CIK 0001413987 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,626 F1 · price: The Issuer issued these shares to the Reporting Person in accordance with its Outside Director Compensation Plan. Read SEC document |
| September 15, 2021 Filed Sep 17, 2021 20:45 UTC | OptimizeRx Corp OPRX · Entity 213 | SaleCommon Stock (pursuant to 10B5-1 plan) | 16,666 | $65.74 | $1,095,622.84 |
DisclosureSEC source: 0001213900-21-048613 · ownership.xml · nonDerivative · entry 1 FEBBO WILLIAM J · CIK 0001413987 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 519,375 F1 · security: These shares sold pursuant to a plan of disposition adopted on May 28, 2021 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| September 13, 2021 Filed Sep 15, 2021 20:45 UTC | OptimizeRx Corp OPRX · Entity 213 | GiftCommon Stock | 8,600 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001213900-21-048251 · ownership.xml · nonDerivative · entry 1 FEBBO WILLIAM J · CIK 0001413987 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 536,041 F1 · shares: Shares represent a charitable gift/donation to the National Philanthropic Trust/William and Vanessa Febbo. The Reporting Person is not a Trustee and has no pecuniary interest or investment discretion. F2 · price: Price is not applicable to acquisitions or dispositions resulting from bona fide gifts. Read SEC document |
| August 16, 2021 Filed Aug 17, 2021 20:46 UTC | OptimizeRx Corp OPRX · Entity 213 | SaleCommon Stock (pursuant to 10B5-1 plan) | 16,666 | $60.46 | $1,007,626.36 |
DisclosureSEC source: 0001213900-21-043480 · ownership.xml · nonDerivative · entry 1 FEBBO WILLIAM J · CIK 0001413987 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 544,641 F1 · security: These shares sold pursuant to a plan of disposition adopted on May 28, 2021 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| June 30, 2021 Filed Jul 2, 2021 19:39 UTC | Modular Medical, Inc. MODD · Entity 7488 | GrantCommon Stock | 4,237 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001019056-21-000405 · febbo.xml · nonDerivative · entry 1 FEBBO WILLIAM J · CIK 0001413987 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,237 F1 · price: The Issuer issued these shares to the Reporting Person in accordance with its Outside Director Compensation Plan. Read SEC document |
| March 25, 2021 Filed Mar 26, 2021 20:45 UTC | OptimizeRx Corp OPRX · Entity 213 | Exercise / conversionStock Option · Derivative | 394,739 | Not disclosed Strike: $3.21 | Not disclosed |
DisclosureSEC source: 0001213900-21-018006 · ownership.xml · derivative · entry 5 FEBBO WILLIAM J · CIK 0001413987 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 394,739 shares Expires 2021-05-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The transactions reported in the above Table 1 Rows 3 and 4 reflect the cashless exercise of a soon to expire stock option. The cashless exercise of the option is reported in two lines. The first line of the cashless exercise transaction is coded M in Column 3 of Table 1 and reports in Column 4 the number of shares issuable upon exercise of the option had cash been paid to exercise the option, together with the exercise price with code A for acquired. The line coded F in Column 3 of Table I relates to the same cashless exercise on the preceding line and reports in Column 4 the number of shares deducted from the total number of shares issuable to pay for the cashless exercise of such options with code D for disposal. The price in Column D reflects the closing price on the date of the cashless exercise. The number of shares on a net basis is actually owned by the Reporting Person after the cashless exercise. The transactions reported in Table II above reflect the disposition of the same stock option whose cashless exercise is disclosed in Table I above. The sales reflected in Table 1, Rows 1 and 2, were sales to generate funds to pay the taxes associated with the cashless exercise. Read SEC document |
| March 25, 2021 Filed Mar 26, 2021 20:45 UTC | OptimizeRx Corp OPRX · Entity 213 | Tax withholdingCommon Stock | 26,710 | $47.44 | $1,267,122.40 |
DisclosureSEC source: 0001213900-21-018006 · ownership.xml · nonDerivative · entry 4 FEBBO WILLIAM J · CIK 0001413987 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 561,307 Read SEC document |
| March 25, 2021 Filed Mar 26, 2021 20:45 UTC | OptimizeRx Corp OPRX · Entity 213 | Exercise / conversionCommon Stock | 394,739 | $3.21 | $1,267,112.19 |
DisclosureSEC source: 0001213900-21-018006 · ownership.xml · nonDerivative · entry 3 FEBBO WILLIAM J · CIK 0001413987 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 588,017 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 25, 2021 Filed Mar 26, 2021 20:45 UTC | OptimizeRx Corp OPRX · Entity 213 | SaleCommon Stock | 80,000 | $46.10 | $3,688,000.00 |
DisclosureSEC source: 0001213900-21-018006 · ownership.xml · nonDerivative · entry 2 FEBBO WILLIAM J · CIK 0001413987 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 193,278 Read SEC document |
| March 24, 2021 Filed Mar 26, 2021 20:45 UTC | OptimizeRx Corp OPRX · Entity 213 | SaleCommon Stock | 20,000 | $50.50 | $1,010,000.00 |
DisclosureSEC source: 0001213900-21-018006 · ownership.xml · nonDerivative · entry 1 FEBBO WILLIAM J · CIK 0001413987 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 273,278 Read SEC document |
| January 07, 2021 Filed Jan 12, 2021 00:04 UTC | OptimizeRx Corp OPRX · Entity 213 | GrantUnvested Restricted Stock Award · Derivative | 28,883 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001213900-21-001538 · ownership.xml · derivative · entry 1 FEBBO WILLIAM J · CIK 0001413987 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,883 Underlying: Common · 28,883 shares Expires 2024-01-07 F1 · derivative.exercise_price: The Reporting Person acquired these shares pursuant to a Restricted Stock Award. The award vests 1/3 at the end of each anniversary from issuance. F1 · price: The Reporting Person acquired these shares pursuant to a Restricted Stock Award. The award vests 1/3 at the end of each anniversary from issuance. F1 · derivative.exercise_date: The Reporting Person acquired these shares pursuant to a Restricted Stock Award. The award vests 1/3 at the end of each anniversary from issuance. Read SEC document |
| December 31, 2020 Filed Jan 5, 2021 21:45 UTC | OptimizeRx Corp OPRX · Entity 213 | Exercise / conversionUnvested Restricted Stock Award · Derivative | 21,186 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001213900-21-000454 · ownership.xml · derivative · entry 6 FEBBO WILLIAM J · CIK 0001413987 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 84,746 shares Expires 2020-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Reporting Person acquired these shares pursuant to a Restricted Stock Award. The award vests 25% at the end of each quarter starting on 3/31/2020, and 21,187, 21,187, 21,186 and 21,186 shares vested as of March 31, 2020, June 30, 2020, September 30, 2020 and December 31, 2020, respectively. F1 · price: The Reporting Person acquired these shares pursuant to a Restricted Stock Award. The award vests 25% at the end of each quarter starting on 3/31/2020, and 21,187, 21,187, 21,186 and 21,186 shares vested as of March 31, 2020, June 30, 2020, September 30, 2020 and December 31, 2020, respectively. Read SEC document |
| December 31, 2020 Filed Jan 5, 2021 21:45 UTC | OptimizeRx Corp OPRX · Entity 213 | Exercise / conversionCommon Stock | 21,186 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001213900-21-000454 · ownership.xml · nonDerivative · entry 3 FEBBO WILLIAM J · CIK 0001413987 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 293,278 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Reporting Person acquired these shares pursuant to a Restricted Stock Award. The award vests 25% at the end of each quarter starting on 3/31/2020, and 21,187, 21,187, 21,186 and 21,186 shares vested as of March 31, 2020, June 30, 2020, September 30, 2020 and December 31, 2020, respectively. Read SEC document |
| September 30, 2020 Filed Jan 5, 2021 21:45 UTC | OptimizeRx Corp OPRX · Entity 213 | Exercise / conversionUnvested Restricted Stock Award · Derivative | 21,186 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001213900-21-000454 · ownership.xml · derivative · entry 5 FEBBO WILLIAM J · CIK 0001413987 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,186 Underlying: Common Stock · 84,746 shares Expires 2020-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Reporting Person acquired these shares pursuant to a Restricted Stock Award. The award vests 25% at the end of each quarter starting on 3/31/2020, and 21,187, 21,187, 21,186 and 21,186 shares vested as of March 31, 2020, June 30, 2020, September 30, 2020 and December 31, 2020, respectively. F1 · price: The Reporting Person acquired these shares pursuant to a Restricted Stock Award. The award vests 25% at the end of each quarter starting on 3/31/2020, and 21,187, 21,187, 21,186 and 21,186 shares vested as of March 31, 2020, June 30, 2020, September 30, 2020 and December 31, 2020, respectively. Read SEC document |
| September 30, 2020 Filed Jan 5, 2021 21:45 UTC | OptimizeRx Corp OPRX · Entity 213 | Exercise / conversionCommon Stock | 21,186 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001213900-21-000454 · ownership.xml · nonDerivative · entry 2 FEBBO WILLIAM J · CIK 0001413987 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 272,092 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Reporting Person acquired these shares pursuant to a Restricted Stock Award. The award vests 25% at the end of each quarter starting on 3/31/2020, and 21,187, 21,187, 21,186 and 21,186 shares vested as of March 31, 2020, June 30, 2020, September 30, 2020 and December 31, 2020, respectively. Read SEC document |
| June 30, 2020 Filed Jul 2, 2020 20:32 UTC | OptimizeRx Corp OPRX · Entity 213 | Exercise / conversionUnvested Restricted Stock Award · Derivative | 21,187 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001213900-20-016579 · ownership.xml · derivative · entry 2 FEBBO WILLIAM J · CIK 0001413987 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,372 Underlying: Common Stock · 84,746 shares Expires 2020-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Reporting Person acquired these shares pursuant to a Restricted Stock Award. The award vests 25% at the end of each quarter starting on 3/31/2020, and 21,187 shares vested as of June 30, 2020. F1 · price: The Reporting Person acquired these shares pursuant to a Restricted Stock Award. The award vests 25% at the end of each quarter starting on 3/31/2020, and 21,187 shares vested as of June 30, 2020. Read SEC document |
| June 30, 2020 Filed Jul 2, 2020 20:32 UTC | OptimizeRx Corp OPRX · Entity 213 | Exercise / conversionCommon Stock | 21,187 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001213900-20-016579 · ownership.xml · nonDerivative · entry 1 FEBBO WILLIAM J · CIK 0001413987 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 229,719 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Reporting Person acquired these shares pursuant to a Restricted Stock Award. The award vests 25% at the end of each quarter starting on 3/31/2020, and 21,187 shares vested as of June 30, 2020. Read SEC document |
| June 24, 2020 Filed Jun 26, 2020 12:45 UTC | OptimizeRx Corp OPRX · Entity 213 | Exercise / conversionStock Option · Derivative | 45,261 | $3.21 Strike: $3.21 | $145,287.81 |
DisclosureSEC source: 0001213900-20-015899 · ownership.xml · derivative · entry 2 FEBBO WILLIAM J · CIK 0001413987 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 394,739 Underlying: Common Stock · 45,261 shares Expires 2021-02-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 24, 2020 Filed Jun 26, 2020 12:45 UTC | OptimizeRx Corp OPRX · Entity 213 | Exercise / conversionCommon Stock | 45,261 | $3.21 | $145,287.81 |
DisclosureSEC source: 0001213900-20-015899 · ownership.xml · nonDerivative · entry 1 FEBBO WILLIAM J · CIK 0001413987 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 208,528 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 31, 2020 Filed Jan 5, 2021 21:45 UTC | OptimizeRx Corp OPRX · Entity 213 | Exercise / conversionUnvested Restricted Stock Award · Derivative | 21,187 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001213900-21-000454 · ownership.xml · derivative · entry 4 FEBBO WILLIAM J · CIK 0001413987 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,559 Underlying: Common Stock · 84,746 shares Expires 2020-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Reporting Person acquired these shares pursuant to a Restricted Stock Award. The award vests 25% at the end of each quarter starting on 3/31/2020, and 21,187, 21,187, 21,186 and 21,186 shares vested as of March 31, 2020, June 30, 2020, September 30, 2020 and December 31, 2020, respectively. F1 · price: The Reporting Person acquired these shares pursuant to a Restricted Stock Award. The award vests 25% at the end of each quarter starting on 3/31/2020, and 21,187, 21,187, 21,186 and 21,186 shares vested as of March 31, 2020, June 30, 2020, September 30, 2020 and December 31, 2020, respectively. Read SEC document |
| March 31, 2020 Filed Jan 5, 2021 21:45 UTC | OptimizeRx Corp OPRX · Entity 213 | Exercise / conversionCommon Stock | 21,187 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001213900-21-000454 · ownership.xml · nonDerivative · entry 1 FEBBO WILLIAM J · CIK 0001413987 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,906 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Reporting Person acquired these shares pursuant to a Restricted Stock Award. The award vests 25% at the end of each quarter starting on 3/31/2020, and 21,187, 21,187, 21,186 and 21,186 shares vested as of March 31, 2020, June 30, 2020, September 30, 2020 and December 31, 2020, respectively. Read SEC document |
| March 11, 2020 Filed Mar 13, 2020 21:21 UTC | OptimizeRx Corp OPRX · Entity 213 | GrantUnvested Restricted Stock Award · Derivative | 84,746 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001213900-20-006361 · ownership.xml · derivative · entry 1 FEBBO WILLIAM J · CIK 0001413987 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,746 Underlying: 12/31/20 · 84,746 shares Expires 2020-12-31 F1 · derivative.exercise_price: The Reporting Person acquired these shares pursuant to a Restricted Stock Award. The award vests 25% at the end of each quarter starting on 3/31/2020. F1 · price: The Reporting Person acquired these shares pursuant to a Restricted Stock Award. The award vests 25% at the end of each quarter starting on 3/31/2020. Read SEC document |
| March 04, 2020 Filed Mar 5, 2020 18:24 UTC | OptimizeRx Corp OPRX · Entity 213 | Exercise / conversionStock Option · Derivative | 30,000 | $3.21 Strike: $3.21 | $96,300.00 |
DisclosureSEC source: 0001213900-20-005495 · ownership.xml · derivative · entry 2 FEBBO WILLIAM J · CIK 0001413987 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 440,000 Underlying: Common Stock · 30,000 shares Expires 2021-02-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 04, 2020 Filed Mar 5, 2020 18:24 UTC | OptimizeRx Corp OPRX · Entity 213 | Exercise / conversionCommon Stock | 30,000 | $3.21 | $96,300.00 |
DisclosureSEC source: 0001213900-20-005495 · ownership.xml · nonDerivative · entry 1 FEBBO WILLIAM J · CIK 0001413987 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 163,267 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 23, 2020 Filed Jan 27, 2020 16:59 UTC | Modular Medical, Inc. MODD · Entity 7488 | GrantOption to purchase common stock · Derivative | 200,000 | $2.25 Strike: $2.25 | $450,000.00 |
DisclosureSEC source: 0001019056-20-000027 · febbo.xml · derivative · entry 1 FEBBO WILLIAM J · CIK 0001413987 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2030-01-23 F1 · security: This option will vest as to one-third of the shares subject to the option on each annual anniversary of January 23, 2020. Read SEC document |
| December 04, 2019 Filed Dec 5, 2019 13:45 UTC | OptimizeRx Corp OPRX · Entity 213 | Exercise / conversionStock Option · Derivative | 30,000 | $3.21 Strike: $3.21 | $96,300.00 |
DisclosureSEC source: 0001213900-19-025356 · ownership.xml · derivative · entry 2 FEBBO WILLIAM J · CIK 0001413987 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 470,000 Underlying: Common Stock · 30,000 shares Expires 2021-02-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 04, 2019 Filed Dec 5, 2019 13:45 UTC | OptimizeRx Corp OPRX · Entity 213 | Exercise / conversionCommon Stock | 30,000 | $3.21 | $96,300.00 |
DisclosureSEC source: 0001213900-19-025356 · ownership.xml · nonDerivative · entry 1 FEBBO WILLIAM J · CIK 0001413987 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,267 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 06, 2019 Filed Nov 6, 2019 21:15 UTC | OptimizeRx Corp OPRX · Entity 213 | PurchaseCommon Stock | 5,000 | $9.50 | $47,500.00 |
DisclosureSEC source: 0001213900-19-022200 · ownership.xml · nonDerivative · entry 1 FEBBO WILLIAM J · CIK 0001413987 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,267 Read SEC document |
| March 28, 2019 Filed Mar 29, 2019 20:17 UTC | OptimizeRx Corp OPRX · Entity 213 | ConversionContingent Stock Grant · Derivative | 80,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001213900-19-005239 · ownership.xml · derivative · entry 2 FEBBO WILLIAM J · CIK 0001413987 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 80,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The reporting person received a contingent stock grant subject to achievement of the Issuer's 2018 year-end revenue performance goals that were achieved for the year. F1 · price: The reporting person received a contingent stock grant subject to achievement of the Issuer's 2018 year-end revenue performance goals that were achieved for the year. F1 · derivative.exercise_date: The reporting person received a contingent stock grant subject to achievement of the Issuer's 2018 year-end revenue performance goals that were achieved for the year. F2 · derivative.expiration_date: Not applicable. Read SEC document |
| March 28, 2019 Filed Mar 29, 2019 20:17 UTC | OptimizeRx Corp OPRX · Entity 213 | GrantCommon Stock | 80,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001213900-19-005239 · ownership.xml · nonDerivative · entry 1 FEBBO WILLIAM J · CIK 0001413987 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,267 F1 · price: The reporting person received a contingent stock grant subject to achievement of the Issuer's 2018 year-end revenue performance goals that were achieved for the year. Read SEC document |
| February 25, 2019 Filed Feb 26, 2019 22:19 UTC | OptimizeRx Corp OPRX · Entity 213 | GrantRestricted Stock Grant · Derivative | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-19-003164 · ownership.xml · derivative · entry 2 FEBBO WILLIAM J · CIK 0001413987 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,000 Underlying: Common Stock · 30,000 shares Expires not disclosed F1 · derivative.exercise_price: Not applicable. F3 · derivative.exercise_date: Each restricted stock grant represents a contingent right to receive one share of the Issuer's common stock. F4 · derivative.expiration_date: The reporting person received a restricted stock grant that may vest on February 1, 2020, subject to achievement of the Issuer's year-end revenue performance goals. Read SEC document |
| February 25, 2019 Filed Feb 26, 2019 22:19 UTC | OptimizeRx Corp OPRX · Entity 213 | OtherOption · Derivative | 100,000 | Not disclosed Strike: $1.07 | Not disclosed |
DisclosureSEC source: 0001213900-19-003164 · ownership.xml · derivative · entry 1 FEBBO WILLIAM J · CIK 0001413987 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500,000 Underlying: Common Stock · 100,000 shares Expires 2021-02-28 F1 · price: Not applicable. F2 · derivative.exercise_date: The Issuer and the Reporting Person amended the Reporting Person's employment agreement to vest his options as of February 28, 2019. Read SEC document |
| December 19, 2018 Filed Dec 20, 2018 13:30 UTC | OptimizeRx Corp OPRX · Entity 213 | PurchaseCommon Stock | 2,000 | $9.94 | $19,880.00 |
DisclosureSEC source: 0001213900-18-017585 · ownership.xml · nonDerivative · entry 1 FEBBO WILLIAM J · CIK 0001413987 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,267 Read SEC document |
| November 07, 2018 Filed Nov 8, 2018 13:45 UTC | OptimizeRx Corp OPRX · Entity 213 | PurchaseCommon Stock | 600 | $16.32 | $9,791.82 |
DisclosureSEC source: 0001213900-18-015112 · ownership.xml · nonDerivative · entry 1 FEBBO WILLIAM J · CIK 0001413987 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,267 Read SEC document |
| June 22, 2018 Filed Jun 25, 2018 20:23 UTC | OptimizeRx Corp OPRX · Entity 213 | PurchaseCommon Stock | 1,000 | $10.50 | $10,500.00 |
DisclosureSEC source: 0001213900-18-008163 · ownership.xml · nonDerivative · entry 1 FEBBO WILLIAM J · CIK 0001413987 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,667 Read SEC document |
| February 01, 2018 Filed Feb 2, 2018 22:16 UTC | OptimizeRx Corp OPRX · Entity 213 | GrantRestricted Stock Grant · Derivative | 240,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-18-001238 · f4020118febbo_optimizerx.xml · derivative · entry 1 FEBBO WILLIAM J · CIK 0001413987 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,740,000 Underlying: Common Stock · 240,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock grant represents a contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: The reporting person received a restricted stock grant that may vest on either February 1, 2019 or February 1, 2020, subject to achievement of the Issuer's year-end revenue performance goals. F3 · derivative.expiration_date: Not applicable. Read SEC document |
| December 01, 2016 Filed Dec 5, 2016 14:15 UTC | OptimizeRx Corp OPRX · Entity 213 | PurchaseCommon Stock | 4,000 | $0.85 | $3,400.00 |
DisclosureSEC source: 0001213900-16-019141 · f4120116febbo_optimizerx.xml · nonDerivative · entry 1 FEBBO WILLIAM J · CIK 0001413987 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,000 Read SEC document |
| November 10, 2016 Filed Nov 14, 2016 14:00 UTC | OptimizeRx Corp OPRX · Entity 213 | PurchaseCommon Stock | 9,000 | $0.90 | $8,100.00 |
DisclosureSEC source: 0001213900-16-018324 · f4111016febbo_optimizerxcorp.xml · nonDerivative · entry 1 FEBBO WILLIAM J · CIK 0001413987 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.